{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:24:42Z","timestamp":1793622282813,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFA1104500"],"award-info":[{"award-number":["2022YFA1104500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370423"],"award-info":[{"award-number":["82370423"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900267"],"award-info":[{"award-number":["81900267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270703"],"award-info":[{"award-number":["82270703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is a progressive condition marked by the abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs), leading to significant remodelling of the pulmonary arteries (PAs). The cyclooxygenase metabolite of arachidonic acid prostaglandin E2 and its receptor EP4 are crucial for maintaining vascular homeostasis. This study aimed to determine the role of EP4 in the pathogenesis of PAH and evaluate the potential of EP4 as a therapeutic target for PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two well-established PAH models, the monocrotaline-induced rat model and hypoxia\/Su5416-induced mouse model, were used in this study. Both pharmacological interventions (including the EP4 antagonist grapiprant and MF498 and the agonist Cay10598) and genetic strategies (including vascular smooth muscle cell [VSMC]-specific EP4 knockout mice and VSMC-specific human EP4 transgenic mice) were used to comprehensively investigate the role of EP4 in the pathogenesis of PAH. Multiple cellular and molecular biology approaches were employed to investigate the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results showed that the pharmacological blockade of the EP4 receptor and genetic deletion of the EP4 gene in VSMCs led to a significant improvement in PAH and PA remodelling. Conversely, pharmacological activation and VSMC-specific overexpression of EP4 exacerbate PAH progression. Further analysis identified annexin A2 (ANXA2) as a critical downstream mediator in EP4-induced PAH progression. Mechanistically, EP4 activation was found to enhance the translation of ANXA2 and phosphorylation of ANXA2 at Thr208 via the cAMP\/PKA pathway, promoting PASMC proliferation and migration through increased nuclear translocation of \u03b2-catenin, a key signalling molecule in the canonical Wnt pathway. Importantly, pharmacological inhibition or genetic deletion of ANXA2 effectively protected PAH in rodents, suggesting its pathogenic role in PAH development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals a crucial pathway involving EP4 and ANXA2 in PAH development and progression. Targeting EP4 and its downstream effector ANXA2 represents promising therapeutic strategies for PAH management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf763","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:33:20Z","timestamp":1757417600000},"page":"1199-1217","source":"Crossref","is-referenced-by-count":12,"title":["EP4\/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-0932","authenticated-orcid":false,"given":"Hu","family":"Xu","sequence":"first","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]},{"name":"Kidney Health Institute, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Ye","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Du","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liang","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhui","family":"Mao","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liang","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huishu","family":"Shao","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowan","family":"Sun","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Yun","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changbiao","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University , Longyan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Xiu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University , Longyan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Su","sequence":"additional","affiliation":[{"name":"Health Science Center, Shenzhen University , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenling","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital, Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]},{"name":"Kidney Health Institute, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfei","family":"Guan","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University , No. 9 West Section Lvshun South Road, Dalian, Liaoning 116044 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-2423","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]},{"name":"Kidney Health Institute, East China Normal University , No. 500, Dongchuan Road, Shanghai 200241 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026030819515892800_ehaf763-B1","doi-asserted-by":"publisher","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030819515892800_ehaf763-B2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030819515892800_ehaf763-B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026030819515892800_ehaf763-B4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2026030819515892800_ehaf763-B5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/d41573-024-00054-y","article-title":"FDA approves Merck & Co\u2019s pulmonary arterial hypertension drug sotatercept","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026030819515892800_ehaf763-B6","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1073\/pnas.1902119116","article-title":"VSMC-specific EP4 deletion exacerbates angiotensin II-induced aortic dissection by increasing vascular inflammation and blood pressure","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026030819515892800_ehaf763-B7","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/cells11172720","article-title":"The prostaglandin E2 receptor EP4 promotes vascular neointimal hyperplasia through translational control of tenascin C via the cAMP\/PKA\/mTORC1\/rpS6 pathway","volume":"11","author":"Xu","year":"2022","journal-title":"Cells"},{"key":"2026030819515892800_ehaf763-B8","doi-asserted-by":"publisher","first-page":"e138505","DOI":"10.1172\/jci.insight.138505","article-title":"Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis","volume":"5","author":"Xu","year":"2020","journal-title":"JCI Insight"},{"key":"2026030819515892800_ehaf763-B9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"2026030819515892800_ehaf763-B10","doi-asserted-by":"publisher","first-page":"H1187","DOI":"10.1152\/ajpheart.00589.2013","article-title":"Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"307","author":"Somanna","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026030819515892800_ehaf763-B11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/jpet.107.134221","article-title":"Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis","volume":"326","author":"Cathcart","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2026030819515892800_ehaf763-B12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00210-008-0298-3","article-title":"Celecoxib but not the combination of celecoxib + atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat","volume":"378","author":"Rakotoniaina","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026030819515892800_ehaf763-B13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12931-022-02056-z","article-title":"Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation","volume":"23","author":"Alqarni","year":"2022","journal-title":"Respir Res"},{"key":"2026030819515892800_ehaf763-B14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s0090-6980(02)00054-0","article-title":"Prostanoid receptor subtypes","volume":"68-69","author":"Tsuboi","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026030819515892800_ehaf763-B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/36342","article-title":"The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth","volume":"390","author":"Nguyen","year":"1997","journal-title":"Nature"},{"key":"2026030819515892800_ehaf763-B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejphar.2007.05.052","article-title":"Stimulation of prostanoid IP and EP2 receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats","volume":"570","author":"Mori","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2026030819515892800_ehaf763-B17","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1161\/ATVBAHA.120.314297","article-title":"Excessive EP4 signaling in smooth muscle cells induces abdominal aortic aneurysm by amplifying inflammation","volume":"40","author":"Hiromi","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026030819515892800_ehaf763-B18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fphar.2018.01518","article-title":"Mechanism of beraprost effects on pulmonary hypertension: contribution of cross-binding to PGE2 receptor 4 and modulation of O2 sensitive voltage-gated K+ channels","volume":"9","author":"Fan","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026030819515892800_ehaf763-B19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.pharmthera.2013.03.006","article-title":"E-type prostanoid receptor 4 (EP4) in disease and therapy","volume":"138","author":"Konya","year":"2013","journal-title":"Pharmacol Ther"},{"key":"2026030819515892800_ehaf763-B20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nrm1661","article-title":"Annexins: linking Ca2+ signalling to membrane dynamics","volume":"6","author":"Gerke","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026030819515892800_ehaf763-B21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/iub.2538","article-title":"Dephosphorylation of annexin A2 by protein phosphatase 1 regulates endothelial cell barrier","volume":"73","author":"Kir\u00e1ly","year":"2021","journal-title":"IUBMB Life"},{"key":"2026030819515892800_ehaf763-B22","doi-asserted-by":"publisher","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation","volume":"7","author":"Seidah","year":"2012","journal-title":"PLoS One"},{"key":"2026030819515892800_ehaf763-B23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.resp.2012.09.009","article-title":"Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation of pulmonary arterial smooth muscle cells","volume":"185","author":"Zeng","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"2026030819515892800_ehaf763-B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbrc.2015.11.073","article-title":"Annexin A2 inhibits the migration of PASMCs stimulated with HPS rat serum by down-regulating the expression of paxillin","volume":"469","author":"Chen","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"2026030819515892800_ehaf763-B25","doi-asserted-by":"publisher","first-page":"2045894018788267","DOI":"10.1177\/2045894018788267","article-title":"Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis","volume":"8","author":"Wade","year":"2018","journal-title":"Pulm Circ"},{"key":"2026030819515892800_ehaf763-B26","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.bbagen.2017.08.024","article-title":"Protein phosphorylation and its role in the regulation of Annexin A2 function","volume":"1861","author":"Grindheim","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2026030819515892800_ehaf763-B27","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1128\/mcb.6.7.2738-2744.1986","article-title":"The protein-tyrosine kinase substrate p36 is also a substrate for protein kinase C in vitro and in vivo","volume":"6","author":"Gould","year":"1986","journal-title":"Mol Cell Biol"},{"key":"2026030819515892800_ehaf763-B28","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/pmic.201200455","article-title":"Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure","volume":"13","author":"Chugh","year":"2013","journal-title":"Proteomics"},{"key":"2026030819515892800_ehaf763-B29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41388-024-02955-z","article-title":"Stabilization of MOF (KAT8) by USP10 promotes esophageal squamous cell carcinoma proliferation and metastasis through epigenetic activation of ANXA2\/Wnt signaling","volume":"43","author":"Li","year":"2024","journal-title":"Oncogene"},{"key":"2026030819515892800_ehaf763-B30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41420-022-01224-w","article-title":"Annexin A2 plays a key role in protecting against cisplatin-induced AKI through beta-catenin\/TFEB pathway","volume":"8","author":"Shen","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026030819515892800_ehaf763-B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molmed.2016.11.005","article-title":"Targeting vascular remodeling to treat pulmonary arterial hypertension","volume":"23","author":"Thompson","year":"2017","journal-title":"Trends Mol Med"},{"key":"2026030819515892800_ehaf763-B32","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1124\/pr.112.007195","article-title":"The prostanoid EP4 receptor and its signaling pathway","volume":"65","author":"Yokoyama","year":"2013","journal-title":"Pharmacol Rev"},{"key":"2026030819515892800_ehaf763-B33","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026030819515892800_ehaf763-B34","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-1128","DOI":"10.12688\/f1000research.14984.1","article-title":"Recent advances in pulmonary arterial hypertension","volume":"7","author":"Wilkins","year":"2018","journal-title":"F1000Res"},{"key":"2026030819515892800_ehaf763-B35","doi-asserted-by":"publisher","first-page":"109674","DOI":"10.1016\/j.celrep.2021.109674","article-title":"Tumor-initiating stem cell shapes its microenvironment into an immunosuppressive barrier and pro-tumorigenic niche","volume":"36","author":"He","year":"2021","journal-title":"Cell Rep"},{"key":"2026030819515892800_ehaf763-B36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13046-019-1219-7","article-title":"The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming","volume":"38","author":"Liu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026030819515892800_ehaf763-B37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/ijms19030727","article-title":"EP4 agonist L-902,688 suppresses EndMT and attenuates right ventricular cardiac fibrosis in experimental pulmonary arterial hypertension","volume":"19","author":"Lai","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026030819515892800_ehaf763-B38","doi-asserted-by":"publisher","first-page":"L349","DOI":"10.1152\/ajplung.00245.2017","article-title":"Prostanoid EP4 agonist L-902,688 activates PPARgamma and attenuates pulmonary arterial hypertension","volume":"314","author":"Li","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026030819515892800_ehaf763-B39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1161\/HYPERTENSIONAHA.122.19397","article-title":"The novel lysosomal autophagy inhibitor (ROC-325) ameliorates experimental pulmonary hypertension","volume":"80","author":"Bao","year":"2023","journal-title":"Hypertension"},{"key":"2026030819515892800_ehaf763-B40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ajh.2012.67","article-title":"Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation","volume":"25","author":"Yang","year":"2012","journal-title":"Am J Hypertens"},{"key":"2026030819515892800_ehaf763-B41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ejphar.2011.03.032","article-title":"Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery","volume":"660","author":"Kobayashi","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"2026030819515892800_ehaf763-B42","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.prostaglandins.2019.106389","article-title":"Prostaglandin E2, a postulated mediator of neurovascular coupling, at low concentrations dilates whereas at higher concentrations constricts human cerebral parenchymal arterioles","volume":"146","author":"Czigler","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026030819515892800_ehaf763-B43","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1084\/jem.20160652","article-title":"Annexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases","volume":"214","author":"Luo","year":"2017","journal-title":"J Exp Med"},{"key":"2026030819515892800_ehaf763-B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026030819515892800_ehaf763-B45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/10\/1199\/64395549\/ehaf763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/10\/1199\/64395549\/ehaf763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:52:09Z","timestamp":1773013929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/10\/1199\/8263951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf763","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,7]]},"published":{"date-parts":[[2025,9,25]]}}}